trending Market Intelligence /marketintelligence/en/news-insights/trending/v_hahKMyUrPTEtjDhKf46g2 content esgSubNav
In This List

US appeals court denies Regeneron plea to review decision in patent case

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US appeals court denies Regeneron plea to review decision in patent case

The U.S. Court of Appeals for the Federal Circuit denied Regeneron Pharmaceuticals Inc.'s request to reconsider a decision against the company in a patent case.

The U.S. District Court for the Southern District of New York in June 2015 concluded that Regeneron made misleading statements to the U.S. Patent Office to obtain U.S. Patent No. 8,502,018.

The patent covers methods of modifying eukaryotic cells.

In July, the Federal Circuit affirmed the decision, concluding that the company made false assertions and withheld information from the patent office.

Regeneron filed a patent infringement case against Merus N.V. in 2014 claiming that the latter infringed on the '018 patent.

Merus responded with counterclaims, asserting that it did not infringe on the patent and that the patent was invalid and unenforceable because it was procured by inequitable conduct, or with an intent to deceive.

Merus prevailed on all counterclaims.